8 completed, 1 active not recruiting. 9 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 8, Active not recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow MoviPrep: new trials by email Literature Review of MoviPrep trials Research Report on MoviPrep
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma MaaT013, Ipilimumab, Nivolumab - Melanoma | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 70 | 2022-01-20 | 2025-08-28 |
| Efficacy and Safety of mAnnitol in Bowel Preparation During Elective Colonoscopy and Comparison With Moviprep® Phase II: NTC015 low dose, Phase II: NTC015 medium dose, Phase II: NTC015 high dose - Elective Colonoscopy | Phase 2 / Phase 3 | Completed | NTC srl | 886 | 2020-06-18 | 2025-12-08 |
| Microbiota Transfer Therapy for Adults With Autism Spectrum Disorder (ASD) Who Have Gastrointestinal Disorders Vancomycin, MoviPrep, Full Spectrum Microbiota - Autism Spectrum Disorder, Gastrointestinal Disorder | Phase 2 | Active not recruiting | Arizona State University | 55 | 2018-01-04 | 2023-01-09 |
| Safety and Efficacy Study of an Edible Colonoscopy Preparation ECP Colon Prep Kit, MoviPrep® - Colon Prep for Colonoscopy | Phase 2 | Completed | Sebela Pharmaceuticals Development LLC | 60 | 2017-11-20 | 2018-03-19 |
| Safety and Tolerability Study of an Edible Colon Preparation NuLYTELY® (PEG 3350), ECP-019, MoviPrep® (PEG 3350) - Bowel Preparation | Phase 2 | Completed | ColonaryConcepts LLC | 69 | 2015-05-01 | 2018-01-29 |
| Beneficial Bacteria Treatment for Autism oral Vancomycin, MoviPrep, Prilosec - Gastrointestinal Problems, Autism Spectrum Disorders | Phase 1 / Phase 2 | Completed | Arizona State University | 18 | 2014-07-01 | 2025-09-12 |
| Pharmacodynamic and Clinical Evaluation of Dose and Taste-optimised Low Volume PEG-based Bowel Cleansing Solutions Using the Split-dosing Intake Regimen in Healthy Subjects and in Subjects Undergoing Screening Colonoscopy NER1006, MOVIPREP - Colon Cancer | Phase 2 | Completed | Norgine | 240 | 2012-10-01 | 2014-11-20 |
| MOVIPREP® Versus PICOLAX® Pilot Study macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate, NA picosulfate magnesium citrate - Colonoscopy | Phase 2 | Completed | Norgine | 65 | 2005-07-01 | 2007-12-17 |
| A Monocentric Study to Investigate a New Low Dose Oral Gut Cleansing Solution NRL994 - Colorectal Cancer | Phase 2 | Completed | Norgine | 36 | 2001-05-01 | 2024-09-19 |
Autism Spectrum Disorder (2) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Gastrointestinal Diseases (1) · Melanoma (1) · Mucopolysaccharidosis IV (1)
Norgine (3) · Arizona State University (2) · Assistance Publique - Hôpitaux de Paris (1) · ColonaryConcepts LLC (1) · NTC srl (1) · Sebela Pharmaceuticals Development LLC (1)
Germany (3) · United States (3) · France (2) · Italy (1) · Russia (1) · United Kingdom (1)
James B Adams, PhD (2) · Gianpiero Manes, Dr. (1) · Mike Geraint, MD (1) · Rudiger Kornberger, MD (1) · Sue Hall (1)
PMID 18179734, PMID 28122648, PMID 30967657, PMID 31146679, PMID 33087514, PMID 36799346, PMID 40786127
2019 (1)